Delivery Order SPE2DB24D1205-SPE2DB25FCZRD
- Not listed
- The Defense Logistics Agency (DLA) awarded a delivery order valued at $15,579.74 to AmerisourceBergen Drug Corp for the supply of Menquadfi vial (0.5mL) under a firm fixed price, non-set-aside contract. The award was issued on July 21, 2025, with an ultimate completion date of July 22, 2025. AmerisourceBergen's Corporate Office location in Conshohocken, Pennsylvania will serve as the place of performance. This delivery order is issued under AmerisourceBergen's larger Indefinite Delivery Contract...
- The Defense Logistics Agency awarded a delivery order valued at $3,656.00 to AmerisourceBergen Drug Corp for the supply of Menquadfi vials (0.5mL) on August 18, 2025, with a completion date of August 19, 2025. This competitively awarded, non-set-aside contract utilizes firm fixed pricing and is classified as a child contract under AmerisourceBergen's larger federal contract vehicle. The place of performance is listed as Conshohocken, Pennsylvania, which serves as the company's corporate...
- The Defense Logistics Agency awarded a delivery order valued at $2,905.76 to AmerisourceBergen Drug Corp for MENQUADFI vials (0.5mL) on August 14, 2025, with completion targeted for August 15, 2025. This firm fixed-price delivery order represents a non-competitive child award under AmerisourceBergen's existing Indefinite Delivery Contract (IDC) with DLA Troop Support Medical (SPE2DX), which carries a $1 billion ceiling through December 2026. The product will be performed at the contractor's...
- The Defense Logistics Agency (DLA) Medical Supply Chain awarded a delivery order to AmerisourceBergen Drug Corp for MENQUADFI vials (0.5ML) with a ceiling value of $8,254.21 under a firm fixed-price contract type. The award was made on August 11, 2025, with an ultimate completion date of August 12, 2025, and will be performed at the contractor's corporate office location in Conshohocken, Pennsylvania. This is a competitively awarded, non-set-aside delivery order issued under...
- The Defense Logistics Agency awarded a delivery order valued at $2,179.32 to AmerisourceBergen Drug Corp for MENQUADFI vials (0.5mL) on August 5, 2025, with completion scheduled for August 6, 2025. This firm fixed-price delivery order, issued without set-aside designation, reflects a competitively awarded transaction under the company's broader pharmaceutical supply relationship with DLA. The place of performance is AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania,...
- The Defense Logistics Agency awarded a delivery order valued at $7,484.58 to AmerisourceBergen Drug Corp for MENQUADFI vial 0.5ML on August 18, 2025, with an ultimate completion date of August 19, 2025. This competitively awarded, firm fixed-price contract represents a pharmaceutical supply delivery to be performed at the contractor's corporate office location in Conshohocken, Pennsylvania. The contract utilizes no set-aside designation and falls under a delivery order contract type,...
- The Defense Logistics Agency (DLA) awarded a delivery order valued at $4,358.64 to AmerisourceBergen Drug Corp for the supply of MENQUADFI vials (0.5ML) under a firm fixed-price contract type. The award, issued on August 1, 2025, with an ultimate completion date of August 4, 2025, represents a non-competitive delivery order without set-aside provisions. AmerisourceBergen Drug Corp, headquartered in Conshohocken, Pennsylvania, will perform this delivery order at its corporate office location in...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on July 31, 2025, for pharmaceutical supplies, specifically MENQUADFI vial 0.5ML, with a ceiling value of $1,452.88. This delivery order utilizes a firm fixed price contract type and represents a child contract under AmerisourceBergen's larger Indefinite Delivery Contract (IDC) with DLA Troop Support Medical, valued at $999,999,999.00 and extending through December 2026. The contract involves no set-aside...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on July 29, 2025, for the supply of MENQUADFI vial 0.5ML, a meningococcal vaccine product. The contract is valued at $2,179.32 with a firm fixed price structure and an ultimate completion date of July 30, 2025. This non-set-aside competitive award represents a child contract under AmerisourceBergen's larger Indefinite Delivery Contract (IDC) with DLA Troop Support Medical (SPE2DX), valued at $999,999,999.00...
- The Defense Logistics Agency awarded a $1,452.88 firm fixed-price delivery order to AmerisourceBergen Drug Corp for the supply of Menquadfi vial 0.5ml, a meningococcal vaccine product. The contract was competitively awarded with no set-aside designation and is scheduled for completion by August 12, 2025. AmerisourceBergen will perform work from its corporate office location in Conshohocken, Pennsylvania, where the company maintains its headquarters as a major pharmaceutical distributor serving...
- SPE2DB24D1205Indefinite Delivery Contract
- SPE2DB24D1205-SPE2DB25FCZRDDelivery Order
The Defense Logistics Agency awarded a delivery order valued at $15,903.80 to AmerisourceBergen Drug Corp for the supply of Menquadfi vials (0.5ML) on August 18, 2025, with an ultimate completion date of August 19, 2025. This firm fixed-price delivery order represents a non-competitive set-aside contract and will be performed at the contractor's corporate office location in Conshohocken, Pennsylvania. The award is issued under AmerisourceBergen's larger Indefinite Delivery Contract with DLA Troop Support Medical (SPE2DX), a comprehensive pharmaceutical prime vendor agreement valued at $999,999,999.00 and extending through December 2026. AmerisourceBergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider, serves as a critical vendor for federal medical procurement, particularly supporting military and veteran healthcare systems. The company's extensive federal contract portfolio demonstrates its capacity to fulfill diverse pharmaceutical and medical supply requirements across multiple therapeutic domains. This delivery order for Menquadfi vials supports the Defense Health Agency's medical supply chain needs and reflects AmerisourceBergen's ongoing role as a key supplier within the DLA's pharmaceutical distribution network serving Department of Defense healthcare programs.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | Not listed | $15.9k | 8/18/25 |